Vinblastin Injection

Introduction

Vinblastine sulfate is a chemotherapy drug used in the treatment of various types of cancer. It is a member of the vinca alkaloid family and is derived from the periwinkle plant (Catharanthus roseus). Vinblastine is used in combination with other drugs to treat cancers such as Hodgkin’s lymphoma, non-Hodgkin’s lymphoma, and testicular cancer.

Uses

Vinblastine sulfate is used for:

Hodgkin’s Lymphoma: As part of combination chemotherapy regimens.
Non-Hodgkin’s Lymphoma: In combination with other drugs to manage the disease.
Testicular Cancer: Often used in combination with other chemotherapeutic agents.
Other Cancers: Including Kaposi’s sarcoma and some solid tumors as determined by a healthcare provider.

Brand Name	Vinblastin
Type	Injection
Weight	10 mg/10 ml
Generic	Vinblastine Sulfate
Manufacturer	City Overseas Ltd.
Available in	English বাংলা

Mechanism of Action

Vinblastine sulfate works by:

Inhibiting Microtubule Formation: It binds to tubulin, preventing the formation of microtubules, which are essential for mitosis. This disrupts the mitotic spindle formation and leads to cell cycle arrest in metaphase.
Inducing Apoptosis: By interfering with cell division, it triggers programmed cell death (apoptosis) in cancer cells.

How Long Does It Take to Work?

The effects of vinblastine sulfate can be observed within weeks of starting treatment, with significant clinical responses often seen after 2-4 cycles of therapy. The exact time frame can vary based on the type of cancer, stage of disease, and individual patient response.

Absorption

Vinblastine sulfate is administered intravenously. It is not given orally due to poor absorption and high toxicity in the gastrointestinal tract. The drug is directly introduced into the bloodstream, where it is distributed throughout the body.

Route of Elimination

Vinblastine sulfate is primarily eliminated through the liver. It undergoes extensive metabolism in the liver, and the metabolites are then excreted in the bile. A small amount of the drug is excreted in the urine.

Dosage

Adult (Intravenous): Initially, 3.7 mg/m², increase dose wkly based on WBC counts in increments of about 1.8 mg/m² until leukocyte count decreases to about 3000/mm³, or max wkly dose of 18.5 mg/m² reached. Do not increase dose if leukocyte count is reduced to approximately 3000 cells/mm³; administer the max dose that does not cause leucopenia for maintenance. Do not increase subsequent doses if onolytic activity occurs before leucopenic effect. Usual dose: 5.5-7.4 mg/m² per wk. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm³.

Child (Intravenous): Initial 2.5 mg/m² of BSA, increased dose at wkly intervals in increments of about 1.25 mg/m² until leukocyte count decreases to about 3000/ mm³, or max wkly dose of 12.5 mg/m² reached. Do not increase dose once leukocyte count reaches approximately 3000 cells/mm³, instead, a dose of 1 increment smaller to be admin at wkly intervals for maintenance i.e. patient receives the max dose that does not cause leucopenia. If onolytic activity is encountered before leucopenic effect, then there is no need to increase subsequent doses. Do not admin next dose, even though 7 days have lapsed unless the leukocyte count has returned to at least 4000/mm³. Duration of maintenance therapy depends on disease state and the antineoplastic agent combination.

The dosage of vinblastine sulfate is individualized based on the type of cancer, patient’s overall health, and response to therapy:

Typical Dosage: 0.1-0.2 mg/kg body weight administered intravenously every 1-3 weeks, depending on the specific regimen and cancer being treated.
Adjustments: Dose adjustments may be necessary based on blood counts, liver function, and other individual factors.

Administration

Vinblastine sulfate is administered intravenously under the supervision of a healthcare professional. It is typically given as an infusion, and careful monitoring is required to prevent extravasation (leakage of the drug outside the vein), which can cause tissue damage.

Side Effects

Common side effects include:

Nausea and Vomiting: Often managed with antiemetic medications.
Bone Marrow Suppression: Leading to reduced white blood cells, red blood cells, and platelets, which increases the risk of infections and bleeding.
Alopecia: Hair loss is a common effect of chemotherapy.
Constipation: Can be managed with dietary changes and medications.
Neuropathy: Numbness or tingling in the hands or feet.

Toxicity

Severe toxicity may include:

Severe Bone Marrow Suppression: Leading to significant anemia, leukopenia, and thrombocytopenia.
Extravasation Injury: Severe tissue damage if the drug leaks outside the vein.
Infection: Increased risk due to bone marrow suppression.

Precautions

Precautions include:

Blood Counts: Regular monitoring of blood counts is essential due to the risk of bone marrow suppression.
Liver Function: Monitor liver function tests, as the drug is metabolized in the liver.
Extravasation Risk: Ensure proper intravenous technique to prevent extravasation.

Interaction

Vinblastine sulfate may interact with:

CYP3A4 Inhibitors: Drugs that inhibit the CYP3A4 enzyme may increase vinblastine levels and toxicity.
Other Chemotherapeutic Agents: Interactions with other drugs used in combination chemotherapy may alter efficacy and side effect profiles.

Disease Interaction

Considerations for specific conditions include:

Pre-existing Liver Disease: Use with caution due to the drug's hepatic metabolism.
Bone Marrow Disorders: Increased risk of severe bone marrow suppression.

Drug Interaction

Potential drug interactions include:

Hepatic Enzyme Inhibitors: Medications that inhibit liver enzymes can increase vinblastine levels.
Other Anticancer Drugs: Careful management is required when used with other chemotherapy agents to avoid cumulative toxicity.

Food Interactions

No significant food interactions have been reported. Patients should follow general dietary guidelines and consult their healthcare provider regarding specific concerns.

Pregnancy Use

Vinblastine sulfate is classified as Category D for pregnancy, meaning there is evidence of risk to the fetus based on human data. It should be used during pregnancy only if the potential benefits outweigh the risks. Pregnant women should consult their healthcare provider for alternative treatments or recommendations.

Lactation Use

It is unknown if vinblastine is excreted in breast milk. Due to potential risks, it is generally advised to avoid breastfeeding during treatment. Consult a healthcare provider for guidance.

Acute Overdose

In case of acute overdose, symptoms may include severe bone marrow suppression, gastrointestinal distress, and neurotoxicity. Immediate medical attention is required, and supportive care should be provided as needed.

Contraindication

Vinblastine sulfate is contraindicated in:

Hypersensitivity: To vinblastine or any of its components.
Pregnancy: Except in cases where the potential benefit outweighs the risk.

Use Direction

Follow the prescribed dosage and administration instructions carefully. Regular monitoring and follow-up with a healthcare provider are crucial to manage side effects and assess response to therapy.

Storage Conditions

Store vinblastine sulfate at 2-8°C (36-46°F). Protect from light and do not freeze. Keep out of reach of children.

Volume of Distribution

The volume of distribution of vinblastine sulfate is approximately 70-90 liters, indicating significant distribution into body tissues.

Half Life

The half-life of vinblastine sulfate is approximately 19-25 hours. This allows for the drug to remain effective in the body over several days.

Clearance

Vinblastine sulfate is primarily cleared through hepatic metabolism and biliary excretion. The clearance rate can be affected by liver function and other patient-specific factors.

See in details version Vinblastin Injection 10 mg/10 ml also Vinblastin Injection 10 mg/10 ml in bangla